Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 16/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | TP53 | P04637 | 1/20 | 0.89 |
| ▸ | PGR | P06401 | 1/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.89 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.89 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | RAB9A | P51151 | 1/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.89 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.89 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilutamide SCHEMBL12670 | 0.94 | AR (1.00) | ARLMNASMN1; SMN2CYP1A2CYP3A4 | |
| Nilutamide SCHEMBL1462011 | 0.94 | AR (1.00) | ARLMNASMN1; SMN2CYP1A2CYP3A4 | |
| Nilutamide SCHEMBL29351021 | 0.94 | AR (1.00) | ARLMNASMN1; SMN2CYP1A2CYP3A4 | |
| Nilutamide SCHEMBL28562851 | 0.93 | AR (0.98) | ARLMNASMN1; SMN2CYP1A2CYP3A4 | |
| Nilutamide SCHEMBL5579273 | 0.91 | AR (0.89) | ARLMNASMN1; SMN2CYP1A2CYP3A4 | |
| Nilutamide SCHEMBL5527279 | 0.86 | AR (0.69) | ARLMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL10324758 | 0.85 | AR (0.81) | ARLMNASMN1; SMN2CYP1A2CYP3A4 | |
| Nilutamide SCHEMBL115340 | 0.84 | AR (0.73) | ARLMNASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL8407306 | 0.83 | AR (0.78) | ARLMNASMN1; SMN2CYP1A2CYP3A4 | |
| Nilutamide SCHEMBL5537957 | 0.83 | AR (0.77) | ARLMNASMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919899-B2 | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability | ZHONG WEI (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117562905-A | Maintenance of immune response during chemotherapy regimen | G1治疗公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117530948-A | Maintenance of immune response during chemotherapy regimen | G1治疗公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-4142710-B1 | SUBSTITUTED 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C] QUINOLIN-2-ONE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | ZHONG WEI (US) | 2024-01-31 | — | — | EP | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023200427-A1 | SUBSTITUTED 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C] QUINOLIN-2-ONE DERIVATIVE CRYSTAL FORM, SALT CRYSTAL FORM, PREPARATION METHOD AND APPLICATION | ZHONG WEI (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230242525-A1 | SUBSTITUTED 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C] QUINOLIN-2-ONE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | ZHONG WEI (US) | 2023-08-03 | — | — | US | disclosed |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116056698-A | Substituted 1- (3, 3-difluoropiperidin-4-yl) -imidazo [4,5-C ] quinolin-2-one compounds with blood brain barrier penetration capability | 钟卫 | 2023-05-02 | — | — | CN | disclosed |
| CN-113677664-A | Tricyclic degradants of IKAROS and AIOLOS | C4医药公司 | 2021-11-19 | — | — | CN | disclosed |
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| CN-110343090-B | Quinazoline derivative salt crystal form, preparation method and application | 威尚（上海）生物医药有限公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-3778589-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| EP-3438107-B1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019196619-A1 | QUINAZOLINE DERIVATIVE SALT-FORM CRYSTAL FORM, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 威尚（上海）生物医药有限公司 | 2019-10-17 | — | — | WO | disclosed |
| WO-2019196622-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | 威尚（上海）生物医药有限公司 | 2019-10-17 | — | — | WO | disclosed |
| EP-3438107-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919899-B2 | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability | ATM, CHEK2, DCK | AR 4095/4885LMNA 2809/4885SMN1; SMN2 2045/4885 |
| US-20230242525-A1 | SUBSTITUTED 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C] QUINOLIN-2-ONE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | ATM, CHEK2, DCK | AR 4095/4885LMNA 2809/4885SMN1; SMN2 2045/4885 |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, FH | AR 2992/4885LMNA 3024/4885SMN1; SMN2 3901/4885 |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | FYN, KDR, FLT1 | AR 3072/4885LMNA 4828/4885SMN1; SMN2 1707/4885 |
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | KDR, FLT4, EGFR | AR 3623/4885LMNA 4107/4885SMN1; SMN2 2531/4885 |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | FYN, KDR, FLT1 | AR 3072/4885LMNA 4828/4885SMN1; SMN2 1707/4885 |
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | KDR, FLT4, EGFR | AR 3623/4885LMNA 4107/4885SMN1; SMN2 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.